Mitsui Chemicals, Inc.

KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. () is excited to announce that the company has successfully developed a funding plan of total 25 billion yen in new Series B funding and raised 22.5 billion yen with the first payment. This significant investment brings the company's total funding to 44 billion yen. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy. Investor Statements DCI Partners Co., Ltd. "We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro." JIC Venture Growth Investments Co., Ltd. "We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases." Kyoto University Innovation Capital Co., Ltd. "We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible." JAFCO Group Co., Ltd. "We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options." Mitsubishi UFJ Capital Co., Ltd. "Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice." Series B investors About Rege Nephro Co., Ltd. Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases. About RN-014 Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time. About RN-032 Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments. SOURCE Rege Nephro CO., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SANTA CLARA, Calif.--( BUSINESS WIRE )-- Fortanix® Inc. , a leader in data-first cybersecurity and pioneer of Confidential Computing , today announced that Xeureka Inc. , a subsidiary of Mitsui & Co. established to engage in early drug discovery research using a state-of-the-art technology, has successfully leveraged Fortanix and NVIDIA Confidential Computing technologies to significantly improve the accuracy of AI models, and is expected to reduce the time and costs associated with drug discovery. The Pharmaceutical Industry Faces Significant Hurdles Established in 2021 by Mitsui & Co. , one of Japan’s largest trading companies, Xeureka provides computational and AI drug discovery support services for pharmaceutical and biotech companies. The organization aims to speed up the discovery of new drugs that can save lives in the face of significant challenges that hamper the pharmaceutical industry: research and development costs are high, often averaging $1 billion to $2 billion per new drug, and development times can average between 10 and 20 years. Additionally, success rates are infamously low, often below 1% on average. Xeureka aims to use advanced technology across all aspects of drug development to improve both the efficiency and effectiveness of new drug research. AI technologies are core to its mission, requiring extensive data sets to power the AI models. However, the data used in pharmaceutical research often includes highly confidential, sensitive, and personally identifiable data, while stakeholders must comply with various global privacy regulations. To successfully leverage this data in full, Xeureka needed a way to pool data from multiple stakeholders while maintaining its confidentiality during use in AI models to power research. Fortanix and NVIDIA Confidential Computing Powers Accelerated Drug Discovery Xeureka partnered with Fortanix and NVIDIA to demonstrate the ability to integrate disparate datasets from multiple sources while maintaining the security and confidentiality of the original sources. Specifically, Fortanix provided the control plane to enable security policy management and orchestrated the use of highly confidential data in a secure environment. Fortanix’s Confidential Computing capabilities include: Data sharing and access control for fast and collaborative data processing to ensure privacy for multiple parties without revealing sensitive information. Modern key management to ensure unified encryption, regardless of the location of the data across hybrid multi-cloud environments. Workflow management to define, manage and track the data collaboration process flow and ensure privacy and security guardrails. In addition, NVIDIA’s secure enclaves with Confidential Computing-enabled NVIDIA H100 Tensor Core GPUs provided the execution environment to run the data, algorithms and AI models, guaranteeing that highly sensitive data assets remained secure and private while in use. A Significant Leap for AI Model Accuracy By enabling confidential data collaboration, Xeureka improved AI model accuracy from 65% to 74% in certain parameters, which will ultimately reduce the time and costs associated with drug discovery. This is also proof of how AI can enhance the effectiveness and efficiency of new drug development while improving the lives of millions of consumers across the globe. "This is a perfect example of the power of Confidential Computing -- rapidly processing extremely large volumes of real patient data required by AI models with the highest level of privacy and security possible," said Anand Kashyap , CEO and co-founder of Fortanix. "We are proud to partner with Xeureka in its quest to improve drug discovery, and we look forward to more advancements in the years to come." "NVIDIA H100 Tensor Core GPUs configured in Confidential Computing mode have proprietary hardware-based cryptographic engines, firewalls, and remote verification to ensure the integrity of the TEE and validate that their confidential workloads are protected while in use on the GPU – in the most performant way possible today,” said Daniel Rohrer, VP of Software Product Security, Architecture and Research at NVIDIA. “NVIDIA technology uniquely provides companies with the ability to speed up drug discovery and development with a high level of security without compromising performance." "AI is foundational to the initiatives we've launched to tangibly transform pharmaceutical research and development, but models require extremely large amounts of data that often contain sensitive or personal information," said Hiroki Makiguchi, CTO at Xeureka. "Confidential Computing from Fortanix and NVIDIA essentially alleviates those privacy and security concerns while also improving model accuracy, which will prove to be a win-win situation for the entire industry.” About Fortanix Fortanix is a global leader in data security. Our unified platform, powered by Confidential Computing, future proofs your data security and makes it simple for organizations to discover, assess, and remediate cybersecurity risks. Our post-quantum-ready cryptographic solutions help organizations thwart cloud and AI data exposure threats and enable secure innovation. Trusted by leading brands and government agencies, Fortanix empowers enterprises to secure their most sensitive data at rest, in motion, and in-use and remain compliant with regulations worldwide. For more information, visit www.fortanix.com .

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The poly(lactic-co-glycolic acid) (PLGA) market size is expected to grow by USD 106.84 million from 2022 to 2027. In addition, the growth momentum of the market will progress at a CAGR of 8.12% during the forecast period, according to Technavio. Growing demand for drug delivery applications is notably driving the poly(lactic-co-glycolic acid) (PLGA) market. However, factors such as Stringent regulations on PLGA may impede market growth. The market is segmented by Application (Personal care and dermatology, Suture, Fracture fixation, and Others), Type (PLGA 50:50, PLGA 75:25, PLGA 85:15, and PLGA 65:35), and Geography (North America, Europe, APAC, South America, and Middle East and Africa). We provide a detailed analysis of 20 companies operating in the poly(lactic-co-glycolic acid) (PLGA) market, including Akina Inc., Alfa Chemistry, Ashland Inc., Bezwada Biomedical LLC, CD Bioparticles, Corbion NV, Creative PEGWorks, Evonik Industries AG, Foster Corp., Huizhou Foryou Medical Devices Co. Ltd., Koninklijke DSM NV, Merck KGaA, Mitsui Chemicals Inc., Nanosoft Polymers, Nomisma Healthcare Pvt. Ltd., Poly Med Inc., Polysciences Inc., SEQENS GROUP, SPECIFIC POLYMERS, and Zeus Co. Inc. The report offers an up-to-date analysis of the market, and to know the exact growth variance and the Y-O-Y growth rate, Request a Sample Report. Continue Reading Technavio has announced its latest market research report titled Global Poly(Lactic-Co-Glycolic Acid) (PLGA) Market 2023-2027 Poly(Lactic-Co-Glycolic Acid) (PLGA) Market 2023-2027: Company Analysis Ashland- The company offers polylactic-co-glycolic acid such as Viatel bioresorbable polymers. This report provides a full list of key companies, their strategies, and the latest developments. Buy Now for detailed company information Poly(Lactic-Co-Glycolic Acid) (PLGA) Market 2023-2027: Segmentation Application The market share growth in the personal care and dermatology segment will be significant during the forecast period. The unique properties of PLGA make it an appropriate component for a range of personal care and dermatological products, such as facial fillers, body contouring devices, and skin substitutes. Moreover, its biodegradability allows PLGA to gradually degrade into lactic acid and glycolic acid within the body, making it an attractive option for facial fillers and other injectable products. Geography North America is estimated to contribute 35% to the growth of the market during the forecast period. The North American market is expected to experience significant growth, primarily driven by the increasing demand from the pharmaceutical sector. The US is a major consumer of PLGA within the region, with wide-ranging applications in the personal care and cosmetics industry. Furthermore, the growth of the poly lactic-co-glycolic acid (PLGA) market in North America is also driven by the favorable research and development (R&D) landscape. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View the PDF Sample Report Related Reports: The global glycolic acid market size is estimated to grow by USD 154.05 million between 2022 and 2027 exhibiting a CAGR of 7.92%. The Formic Acid (HCOOH) Market size is estimated to grow at a CAGR of 4.88% between 2022 and 2027. The market size is forecast to increase by USD 485.04 million. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Application Market Segmentation by Type Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio